2 terminated, 1 active not recruiting, 1 completed, 1 recruiting. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
Follow Nanobiotix: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer NBTXR3 - Locally-Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-03-27 | 2026-09-18 |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NBTXR3, SABR, Nivolumab - Radiotherapy, Immunotherapy | Phase 1 | Active not recruiting | Nanobiotix | 145 | 2019-01-16 | 2025-10-24 |
| NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT - Prostate Cancer | Phase 1 / Phase 2 | Terminated | Nanobiotix | 5 | 2017-11-15 | 2021-05-10 |
| NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers NBTXR3, IL or IA injection + SBRT - Liver Cancer | Phase 1 / Phase 2 | Terminated | Nanobiotix | 23 | 2016-01-28 | 2021-05-10 |
| NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity NBTXR3 - Adult Soft Tissue Sarcoma | Phase 1 | Completed | Nanobiotix | 22 | 2011-10-01 | 2020-10-06 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Liver Neoplasms (1) · Mouth Neoplasms (1) · Oropharyngeal Neoplasms (1) · Prostatic Neoplasms (1) · Sarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Nivolumab (1) · Radiosurgery (1) · Radiotherapy, Intensity-Modulated (1) · pembrolizumab (1)
United States (3) · France (2)
Adam Dicker, MD (1) · Aileen Chen, MD (1) · Pavel Tyan, MD (1)